Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aurora004: Benmelstobart + Anlotinib + Chemo-Radiotherapy in 1L LS-SCLC
NCT07538258Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in small cell lung cancer (SCLC). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07538258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538258.